Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

INTRODUCTION - The presence of circulating tumor cells (CTCs) is an established marker for prognosis in men with castration-resistant prostate cancer. A cutoff of ≥5 CTCs/7.5ml blood in the CellSearch Epithelial Cell Test has been shown to stratify prognostic groups and predict outcome of abiraterone treatment.

In contrast, the value of CTC detection in men with localized prostrate cancer before radical prostatectomy (RP) is unknown.

MATERIALS AND METHODS - A total of 152 patients treated with RP between 06/2009 and 09/2009 were included. Peripheral venous blood drawn the day before RP was evaluated for CTCs by the CellSearch system. The detection of CTCs was correlated with prostate-specific antigen (PSA) and the histopathological outcome of the RP specimen. A cutoff of 0 vs. ≥1 CTC/7. 5ml blood was defined as the threshold for positive vs. negative CTC status.

RESULTS - Median age was 62 years and median PSA was 6. 7ng/dl. Staging revealed 62. 5% pT2, 26. 3% pT3a, and 11. 2% pT3b tumors, and high-grade disease (≥Gleason 4+3) was determined in 25. 6% of patients. CTCs were detected in 17 patients (11%) with a median CTC count/7. 5ml of 1 (range: 1-clusters with>100 epithelial cells) without significant correlations to PSA levels, pT stage, or Gleason scores. Postoperative pT stage was a significant predictor of biochemical recurrence (BCR) in univariable logistic regression models and as a composite measure together with positive CTC counts (P<0. 0001). CTC positivity alone tended to have a higher hazard ratio for BCR, but this was not statistically significant (P = 0. 1). After a median follow-up of 48 months, there was no significant difference in BCR-free survival between patients with or without CTCs (P = 0. 7).

CONCLUSIONS - Using the CellSearch system, we infrequently detected CTCs in patients with localized tumors before RP. The detection of CTCs did not correlate significantly with PSA, disease characteristics, or the development of BCR. However, larger cohorts with extended follow-up are needed to validate our findings.

Urologic oncology. 2016 Jan 12 [Epub ahead of print]

Christian P Meyer, Klaus Pantel, Pierre Tennstedt, Petra Stroelin, Thorsten Schlomm, Hans Heinzer, Sabine Riethdorf, Thomas Steuber

Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. , Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. , Martini-Clinic Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe